269 related articles for article (PubMed ID: 21689142)
1. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
Kelly RP; Close SL; Farid NA; Winters KJ; Shen L; Natanegara F; Jakubowski JA; Ho M; Walker JR; Small DS
Br J Clin Pharmacol; 2012 Jan; 73(1):93-105. PubMed ID: 21689142
[TBL] [Abstract][Full Text] [Related]
2. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
[TBL] [Abstract][Full Text] [Related]
3. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
4. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Small DS; Farid NA; Payne CD; Konkoy CS; Jakubowski JA; Winters KJ; Salazar DE
Clin Pharmacokinet; 2010 Dec; 49(12):777-98. PubMed ID: 21053990
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
Small DS; Payne CD; Kothare P; Yuen E; Natanegara F; Teng Loh M; Jakubowski JA; Richard Lachno D; Li YG; Winters KJ; Farid NA; Ni L; Salazar DE; Tomlin M; Kelly R
Clin Ther; 2010 Feb; 32(2):365-79. PubMed ID: 20206794
[TBL] [Abstract][Full Text] [Related]
6. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Ernest CS; Small DS; Rohatagi S; Salazar DE; Wallentin L; Winters KJ; Wrishko RE
J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):593-618. PubMed ID: 19023649
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Varenhorst C; James S; Erlinge D; Brandt JT; Braun OO; Man M; Siegbahn A; Walker J; Wallentin L; Winters KJ; Close SL
Eur Heart J; 2009 Jul; 30(14):1744-52. PubMed ID: 19429918
[TBL] [Abstract][Full Text] [Related]
10. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
12. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C
Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
[TBL] [Abstract][Full Text] [Related]
14. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
17. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y
Zhang Y; Zhu X; Zhan Y; Li X; Liu C; Zhu Y; Zhang H; Wei H; Xia Y; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li Y; Ding Y; Zhong D
Br J Clin Pharmacol; 2020 Sep; 86(9):1860-1874. PubMed ID: 32267573
[TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Farid NA; Small DS; Payne CD; Jakubowski JA; Brandt JT; Li YG; Ernest CS; Salazar DE; Konkoy CS; Winters KJ
Pharmacotherapy; 2008 Dec; 28(12):1483-94. PubMed ID: 19025429
[TBL] [Abstract][Full Text] [Related]
19. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
Kitazono T; Ikeda Y; Nishikawa M; Yoshiba S; Abe K; Ogawa A
J Thromb Thrombolysis; 2018 Nov; 46(4):488-495. PubMed ID: 30074128
[TBL] [Abstract][Full Text] [Related]
20. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
